Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05592483 · ClinicalTrials.gov registry record
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 78
- Enrollment target
NCT05592483: Clinical Trial study, sponsored by AstraZeneca.
NCT05592483 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 78 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05592483 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 78 participants
- Enrollment target
Study Summary
This study will collect real-world clinical and patient reported outcomes (PRO) and diary data from eligible patients with documented Human Epidermal Growth Factor Receptor 2 (HER2+) \[globally\] or HER2-low \[North America only\] in routine clinical practice.
Primary Outcome
Real-world time to next treatment will be evaluated. rwTTNT is defined as the length of time from date of first T-Dxd administration to the date the patient received an administration of their next systemic treatment regimen or to their date of death if there is a death prior to having another systemic treatment regimen.
Interventions
- OTHER None (Observational Study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2023-07-07 |
| Est. Completion | 2024-05-29 |
Why NCT05592483 stopped before completion
NCT05592483 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 78 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which None (Observational Study) is the first listed.
NCT05592483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05592483 about?
NCT05592483 is a clinical study titled "An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer". This study will collect real-world clinical and patient reported outcomes (PRO) and diary data from eligible patients with documented Human Epidermal Growth Factor Receptor 2 (HER2+) \[globally\] or HER2-low \[North America only\] in routine clinical practice.
What is the current status of trial NCT05592483?
This trial is currently terminated. The enrollment target is 78 participants. The study started on 2023-07-07. Estimated completion is 2024-05-29.
What interventions are being tested in trial NCT05592483?
The interventions under investigation include: None (Observational Study) (OTHER).
Who is sponsoring clinical trial NCT05592483?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI